Biovail to sell Spectral's tests in Canada:
This article was originally published in Clinica
Biovail subsidiary Crystaal is to market Spectral Diagnostics' rapid test panel of cardiac markers in Canada. Crystaal has a national sales operation which is focused on cardiovascular and acute care hospitals and will replace Toronto-based Spectral's own direct selling effort, though Spectral will continue to provide support.
You may also be interested in...
Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma
The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program.
Johnson & Johnson believes personalization via digital holds the key to smoking cessation success as it launches in the UK its app-supported Nicorette QuickMist SmartTrack product.